Condensed Financial Information of Parent Company

12 Months Ended

Dec. 31, 2022

Condensed Financial Information Disclosure [Abstract]

Condensed Financial Information of Parent Company

17. Condensed Financial Information of Parent Company

GoodRx Holdings, Inc. has no material assets or standalone operations other than its ownership in its consolidated subsidiaries. Under the terms of debt agreements entered into by GoodRx, a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc., GoodRx is restricted from making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. These restrictions have resulted in the restricted net assets (as defined in Rule 1-02 of Regulation S-X) of GoodRx and its subsidiaries to exceed 25% of the consolidated net assets of GoodRx Holdings, Inc. and its subsidiaries.

The condensed financial information is presented on a “parent-only” basis, and GoodRx Holdings, Inc.’s investment in its subsidiary is stated at cost plus equity in loss of subsidiary less distributions received from subsidiary since the date of acquisition. GoodRx Holdings. Inc.’s share of net loss of its subsidiary is included in net loss using the equity method of accounting.

During 2022, 2021 and 2020, GoodRx Holdings, Inc. received no dividends from its subsidiary.

The following table presents the parent-only balance sheets of GoodRx Holdings, Inc.:

	December 31,
(in thousands, except par values)	2022			2021
Assets
Cash	$	5		$	5
Other asset		—			80
Investment in subsidiary, net of distributions		814,822			831,595
Total assets	$	814,827		$	831,680
Liabilities and stockholders' equity
Total liabilities	$	—		$	—
Stockholders' equity
Preferred stock, $0.0001 par value		—			—
Common stock, $0.0001 par value		40			40
Additional paid-in capital		2,263,322			2,247,347
Accumulated deficit		(1,448,535	)		(1,415,707	)
Total stockholders' equity		814,827			831,680
Total liabilities and stockholders' equity	$	814,827		$	831,680

The following table presents the parent-only statements of operations of GoodRx Holdings, Inc.:

	Year Ended December 31,
(in thousands)	2022			2021			2020
Equity in loss of subsidiary	$	(32,828	)	$	(25,254	)	$	(293,623	)
Net loss	$	(32,828	)	$	(25,254	)	$	(293,623	)

The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc.:

	Year Ended December 31,
(in thousands)	2022			2021			2020
Cash flows from operating activities
Net loss	$	(32,828	)	$	(25,254	)	$	(293,623	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity in loss of subsidiary		32,828			25,254			293,623
Changes in assets and liabilities:
Other asset		80			(23	)		90
Other current liabilities		—			(87	)		87
Net cash provided by (used in) operating activities		80			(110	)		177
Cash flows from investing activities
Distribution from (investment in) subsidiary		113,117			22,777			(914,434	)
Net cash provided by (used in) investing activities		113,117			22,777			(914,434	)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of    underwriting discounts and commissions		—			—			891,793
Proceeds from private placement with a related party		—			—			100,000
Repurchases of Class A common stock		(101,721	)		—			—
Payments of initial public offering issuance costs		—			—			(4,937	)
Proceeds from exercise of stock options		9,159			35,021			5,343
Proceeds from early exercise of stock options		—			—			667
Employee taxes paid related to net share settlement of equity awards		(20,635	)		(57,688	)		(78,714	)
Net cash (used in) provided by financing activities		(113,197	)		(22,667	)		914,152
Net change in cash		—			—			(105	)
Cash
Beginning of period		5			5			110
End of period	$	5		$	5		$	5